Literature DB >> 7799091

PET-FDG of pleomorphic xanthoastrocytoma.

I Bicik1, R Raman, J J Knightly, G Di Chiro, M J Fulham.   

Abstract

A young patient with pleomorphic xanthoastrocytoma (PXA), a usually benign cerebral tumor, had two recurrences in a short time period. The clinical, pathological and neuroradiological features, including PET with [18F]-fluorodeoxyglucose (FDG), are presented. The PET-FDG study revealed the recurrent tumor to be hypermetabolic. The diagnosis was confirmed histopathologically. As the clinical outcome of patients harboring PXA is not easy to predict because of possible recurrence and/or transformation into more aggressive gliomas, we discuss the predictive indicators of more aggressive clinical behavior.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7799091

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  A surgically treated case of Lhermitte-Duclos disease with a precise natural history and high uptake of FDG on PET.

Authors:  Yuko Goto; Naoya Hashimoto; Yoshiko Okita; Tetsu Goto; Carter Rabo; Hiroshi Hirayama; Yoshiharu Horikawa; Manabu Kinoshita; Naoki Kagawa; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2009-11-12       Impact factor: 4.130

2.  Evaluation of pleomorphic xanthoastrocytoma by use of positron emission tomography with.

Authors:  N Tsuyuguchi; Y Matsuoka; I Sunada; Y Matsusaka; M Haque
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

3.  Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.